Tofacitinib: The First Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis

Annals of Pharmacotherapy

Volumn 47, Issue 11, 2013, Pages 1524-1531

  Vyas, Deepti ^a   O'Dell, Kate M ^a   Bandy, Jason L ^a   Boyce, Eric G ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

CP 690550; Janus kinase (JAK) inhibitor; rheumatoid arthritis; tofacitinib

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ETANERCEPT; FLUCONAZOLE; GOLIMUMAB; INFLIXIMAB; KETOCONAZOLE; METHOTREXATE; PARACETAMOL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SYMPONI; TACROLIMUS; TOCILIZUMAB; TOFACITINIB; UNCLASSIFIED DRUG;

CELLULITIS; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ACTIVITY SCORE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES ZOSTER; HUMAN; HYPERTENSION; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); MYCOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

CP-690550; JANUS KINASE (JAK) INHIBITOR; RHEUMATOID ARTHRITIS; TOFACITINIB;

ARTHRITIS, RHEUMATOID; ARYL HYDROCARBON HYDROXYLASES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; JANUS KINASES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 84889019481     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013512790     Document Type: Review

References (26)

1. Aletaha D,Neogi T,Silman AJ,et al.2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.Arthritis Rheum. 2010;62:2569-2581.
2. Scott DL,Wolfe F,Huizinga TWJ.Rheumatoid arthritis.Lancet. 2010;376:1094-1108.
3. Tak PP,Kalden JR.Advances in rheumatology: new targeted therapeutics.Arthritis Res Ther. 2011;13:1-14.
4. Singh JA,Furst DE,Bharat A,et al.2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.Arthritis Care Res. 2012;64:625-639.
5. Orme ME,MacGilchrist KS,Mitchell S,et al.Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70.Biologics. 2012;6:429-464.
6. Singh JA,Christensen R,Wells GA,et al.Biologics for rheumatoid arthritis: an overview of Cochrane reviews.Cochrane Database Syst Rev. 2009; (4):.
7. Bruce SP,Boyce EG.Update on abatacept: a selective costimulation modulator for rheumatoid arthritis.Ann Pharmacother. 2007;41:1153-1162.
8. Boyce EG,Halilovic J,Stan-Ugbene O.Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.Clin Ther. 2010;32:1681-1703.
9. Tofacitinib (Xeljanz®) [package insert]. http://labeling.pfizer.com/ShowLabeling.aspx?id=959. Accessed May 10, 2013.
10. Jiang JK,Ghoreschi K,Deflorian F,et al.Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d] pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).J Med Chem. 2008;51:8012-8018.
11. Migita K,Komori A,Torigoshi T,et al.CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.Arthritis Res Ther. 2011;13:R72.
12. Pincus T.The American College of Rheumatology (ACR) Core Data Set and derivative "patient only" indices to assess rheumatoid arthritis.Clin Exp Rheumatol. 2005;23:S109-S113.
13. Kremer JM,Bloom BJ,Breedveld FC,et al.The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.Arthritis Rheum. 2009;60:1895-1905.
14. Tanaka Y,Suzuki M,Nakamura H,Toyoizumi S,Zwillich SH.Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.Arthritis Care Res. 2011;63:1150-1158.
15. Fleischmann R,Cutolo M,Genovese MC,et al.A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.Arthritis Rheum. 2012;64:617-629.
16. Kremer JM,Cohen S,Wilkinson BE,et al.A phase IIb dose-ranging study of the ORAL JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.Arthritis Rheum. 2012;64:970-981.
17. Fleischmann R,Kremer J,Cush J,et al.Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.N Engl J Med. 2012;367:495-507.
18. van Vollenhoven RF,Fleischmann R,Cohen S,et al.Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.N Engl J Med. 2012;367:508-519.
19. Burmester GR,Blanco R,Charles-Schoeman C,et al.Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomized phase 3 trial.Lancet. 2013;381:451-460.
20. Van der Heijde D,Tanaka Y,Fleischmann,et al.Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.Arthritis Rheum. 2013;65:559-570.
21. Advisory Committee Meeting Tofacitinib for the Treatment of Rheumatoid Arthritis (NDA 203214). Briefing document. May9, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960.pdf. Accessed October 28, 2013.
22. Pfizer. A study to evaluate both the efficacy and safety profile of CP-690,550 in patients with moderately to severely active ulcerative colitis (OCTAVE). http://clinicaltrials.gov/ct2/show/NCT01458951?term=tofacitinib&rank=15NCT01458951. Accessed October 28, 2013.
23. Pfizer. A 6-month study of CP-690,550 versus tacrolimus in kidney transplant patients. http://clinicaltrials.gov/ct2/show/NCT00106639?term=tofacitinib&rank=21NCT00106639. Accessed October 28, 2013.
24. Pfizer. Dose-ranging study of tofacitinib in adults with active ankylosing spondylitis. http://clinicaltrials.gov/ct2/show/study/NCT01786668?term=tofacitinib&rank=5NCT01786668. Accessed October 28, 2013.
25. Pfizer. Multiple dose escalation study in medically stable subjects with psoriasis. http://clinicaltrials.gov/ct2/show/NCT01736696?term=tofacitinib&rank=18NCT01736696. Accessed October 28, 2013.
26. HarperM. Xeljanz, A cheaper-but-expensive $25,000-a-year Pfizer pill for rheumatoid arthritis, gets FDA green light. http://www.forbes.com/sites/matthewherper/2012/11/06/xeljanz-a-25000-pfizer-arthritis-pill-gets-fda-green-light/. Accessed February 25, 2013.